ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.417,55
0,62%
S&P 500
5.459,10
1,11%
Dow Jones
40.589,34
1,64%
Euro vs US Dollar
1,08725
0,00%
Bitcoin
67.873,58
-0,06%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. CytomX Therapeutics Inc (CTMX)

  7. CytomX Therapeutics Inc (CTMX) News

CTMX CytomX Therapeutics Inc

1,46
0,04 (2,82%)
27 Jul 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
CytomX Therapeutics Inc CTMX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,04 2,82% 1,46 01:57:35
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
1,45 1,4305 1,51 1,50 1,42
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
18.6.202414:00GLOBECytomX Therapeutics to Present at the H.C. Wainwright 2nd..
17.6.202422:35EDGAR2Form 8-K - Current report
17.6.202422:15GLOBECytomX Therapeutics Promotes Chris Ogden to Chief Financial..
14.6.202422:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.5.202422:05GLOBECytomX Therapeutics to Present at the Jefferies Global..
17.5.202423:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.5.202423:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.5.202423:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.5.202423:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.5.202423:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.5.202422:01EDGAR2Form 8-K - Current report
16.5.202422:15GLOBECytomX Therapeutics Announces New Employment Inducement..
13.5.202422:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08.5.202422:41EDGAR2Form 8-K - Current report
08.5.202422:10GLOBECytomX Therapeutics Announces Positive Initial Phase 1a Dose..
08.5.202422:04EDGAR2Form 8-K - Current report
08.5.202422:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07.5.202422:15GLOBECytomX Therapeutics Announces Clinical Collaboration with..
01.5.202414:00GLOBECytomX Therapeutics to Report First Quarter 2024 Results and..
08.4.202414:00GLOBECytomX Therapeutics Announces First Patient Dosed with..
03.4.202414:00GLOBECytomX Therapeutics Announces Nomination of Second Clinical..
21.3.202413:00GLOBECytomX Therapeutics Appoints Dr. Zhen Su to Board of..
18.3.202413:00GLOBECytomX Therapeutics Announces Milestone Achievement in..
11.3.202421:30EDGAR2Form S-8 - Securities to be offered to employees in employee..
11.3.202421:10GLOBECytomX Therapeutics Reports 2023 Financial Results and..
11.3.202421:02EDGAR2Form 8-K - Current report
11.3.202421:00EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
11.3.202411:39IHMARKETNEWSU.S. Index Futures Dip Ahead of Inflation Data and Oracle’s..
04.3.202414:00GLOBECytomX Therapeutics to Report Fourth Quarter and Full Year..
27.2.202414:00GLOBECytomX Therapeutics to Present at Upcoming March Investor..
24.1.202414:00GLOBECytomX Therapeutics Announces FDA Clearance of IND..
20.1.202402:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.1.202402:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.1.202402:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.1.202402:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.1.202402:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.1.202414:00GLOBECytomX Therapeutics to Present at the B. Riley Securities..
04.1.202414:00GLOBECytomX Therapeutics Outlines 2024 Company Priorities and..
22.12.202322:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.12.202322:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.12.202322:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.12.202322:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.12.202314:00GLOBECytomX Therapeutics to Present at the 42nd Annual J.P...
20.12.202301:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.12.202301:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.12.202301:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.12.202301:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.11.202322:15GLOBECytomX Therapeutics Reports Third Quarter 2023 Financial..
07.11.202322:05EDGAR2Form 8-K - Current report
07.11.202322:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Kürzlich von Ihnen besucht

NASDAQ
CTMX
CytomX Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten